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Background: Lysosomal storage disorders are a heterogeneous group of approximately 50 monogenically inherited
orphan conditions. A defect leads to the storage of complex molecules in the lysosome, and patients develop a
complex multisystemic phenotype of high morbidity often associated with premature death. More than 30 years
ago the Orphan Drug Act of 1983 passed the United States legislation intended to facilitate the development of
drugs for rare disorders.
We directed our efforts in assessing which lysosomal diseases had drug development pressure and what distinguished
those with successful development and approvals from diseases not treated or without orphan drug designation.
Methods: Analysis of the FDA database for orphan drug designations through descriptive and comparative statistics.
Results: Between 1983 and 2013, fourteen drugs for seven conditions received FDA approval. Overall, orphan drug
status was designated 70 times for 20 conditions. Approved therapies were enzyme replacement therapies (N = 10),
substrate reduction therapies (N = 1), small molecules facilitating lysosomal substrate transportation (N = 3). FDA
approval was significantly associated with a disease prevalence higher than 0.5/100,000 (p = 0.00742) and clinical
development programs that did not require a primary neurological endpoint (p = 0.00059). Orphan drug status was
designated for enzymes, modified enzymes, fusion proteins, chemical chaperones, small molecules leading to substrate
reduction, or facilitating subcellular substrate transport, stem cells as well as gene therapies.
Conclusions: Drug development focused on more common diseases. Primarily neurological diseases were neglected.
Small clinical trials with either somatic or biomarker endpoints were successful. Enzyme replacement therapy was the
most successful technology. Four factors played a key role in successful orphan drug development or orphan drug
designations: 1) prevalence of disease 2) endpoints 3) regulatory precedent, and 4) technology platform. Successful
development seeded further innovation.
Keywords: Orphan disease, Drug development, Small clinical trialsBackground
Lysosomal storage disorders
Lysosomal storage disorders (LSDs) are a clinically het-
erogeneous group of more than 40 inherited orphan
conditions. Their prevalence was determined in various
surveys to 13 per 100,000 live births (=1 in 7700) in
Australia [1], 14 per 100,000 live births (=1 in 7143) in
the Netherlands [2], 7.6 per 100,000 live births (=1 in* Correspondence: markus.ries@uni-heidelberg.de
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unless otherwise stated.13,158) in British Columbia [3], and 25 per 100,000 live
births (=1 in 4000) in Portugal [4]. These diseases share
a common pathobiochemical leitmotiv: a genetic defect
leads to the storage of complex non-metabolized mole-
cules in the lysosome. The biochemical identification of
this storage material led to the traditional classification
of LSDs into lipidoses (including sphingolipidoses),
mucopolysaccharidoses (MPSs), glycogenosis, cystinosis,
mucolipidoses, oligosaccharidoses, and neuronal ceroid
lipofuscinoses. Despite the common mechanism, each of
these disorders is distinct with its own pathophysiology and
clinical presentation. LSDs are in general multisystemic,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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creased life-expectancy that can manifest within a heteroge-
neous somatic and neurological spectrum such as hydrops
fetalis, dysmorphism, dysostosis multiplex, hepatospleno-
megaly, central nervous system disease, ophthalmologic,
cardiovascular, renal, or cutaneous disease features [5].
U.S. orphan drug act
Whereas the impetus to develop drugs is driven by un-
met medical need, from a pharmaceutical company's
perspective, this is predicated on returns on investment,
ultimately influenced by the likelihood of success in clin-
ical trials and commercialization. The US Orphan Drug
Act passed in 1983 with the goal to stimulate the invest-
ment into the development of medicines for rare dis-
eases through various incentives, such as seven years'
marketing exclusivity, tax credit for 50% of clinical trial
costs, protocol assistance, Food and Drug Administration
fee waiver, and orphan products grants program [6]. By
December 2013, a total of 456 orphan indications were ap-
proved by the FDA [7].
The key factors for successful drug development of
therapies for lysosomal storage disorders have not been
systematically analyzed. We therefore directed our ef-
forts in assessing which lysosomal diseases had drug de-
velopment pressure and what distinguished those with
successful development and approvals from diseases not
treated or with no orphan drug designations. Neurological
endpoints were a focus of this study because many lyso-
somal storage disorders are neurological conditions. We
analyzed whether disease prevalence, technology plat-
forms, endpoints in clinical trials, and regulatory prece-
dent were associated with successful drug development.
Methods
Data acquisition
We searched the FDA database for orphan drug designa-
tions with pertinent keywords for all lysosomal storage
disorders at http://www.accessdata.fda.gov/scripts/opdlist-
ing/oopd/. Start date of data entry was 01/01/1983. All
data entries until 11/30/2013 were considered.
Epidemiological data on rare disorders were extracted
from the Orphanet Report series [8]. Information on
clinical studies were obtained from clinicaltrials.gov.
In order to account for publication bias, data on regis-
tration studies were obtained from the current FDA ap-
proved drug label accessed at http://www.accessdata.fda.
gov/scripts/cder/drugsatfda/.
Definitions
Pharmacological compounds were categorized into the
following technology platforms based on their biochem-
ical and therapeutic characteristics: enzyme replacement
therapy, substrate reduction therapy, small moleculesfacilitating intracellular substrate transport, chemical
chaperones, gene therapy, stem cell therapy, and others
(such as adjunctive therapies). Regulatory precedent was
defined as a drug approval by the FDA in the same or a
clinically very similar disease, such as the different forms
of mucopolysaccharidoses (MPSs). Time to FDA ap-
proval was defined as the time period from orphan drug
designation until approval by the FDA.
Statistical analysis
Characteristics from each of the identified pharmaco-
logical compounds were summarized using descriptive
statistics. Continuous variables were summarized with
mean, standard deviation, median, minimum and max-
imum values. Categorical variables were summarized with
frequencies and percentages. Key compound characteris-
tics, including requirement for neurological endpoints in
clinical trials, regulatory precedent, disease prevalences
(categorized either as <5/1,000,000 or ≥ 5/100,000) were
compared for those compounds receiving orphan drug
designation as well as receiving FDA approval to deter-
mine if associations existed. Tests for associations between
categorical variables were performed using Fisher’s Exact
Test as a result of low cell counts, where a two-sided p-
value < 0.05 was considered statistically significant. All
statistical analyses were performed using SAS Enterprise
Guide version 9.1 (SAS, Cary, NC, USA).
Results
Successfully developed therapies
From 1983 until 2013, fourteen drugs for seven lyso-
somal storage disorders received FDA approval (Figure 1,
Table 1). Two conditions had multiple drug approvals:
Gaucher disease (N = 5) and cystinosis (N = 3). Five con-
ditions had one FDA drug approval, respectively: Fabry
disease, Pompe disease, MPS I, MPS II, and MPS VI
(Figure 2). The first drug approved with orphan designa-
tion for a lysosomal storage disorder was alglucerase for
Gaucher disease in 1991.
Alglucerase had the first orphan drug designation which
occurred in 1985. Most designations in a single year were
granted in 2008 and 2013 with nine designations per year,
respectively (Figures 1 and 3). From 1983 until 2013, or-
phan drug status was designated 70 times for 20 condi-
tions of lysosomal storage disorders. Five diseases had a
single orphan drug designation and 15 diseases had
multiple orphan drug designations (Figure 4). Four des-
ignations were withdrawn. The mean (standard devi-
ation) time between orphan drug designation and
approval was 6.2 (3.9) years with a median of 5.5 years
and a range of 1 – 15 years (N = 14). Figure 2 demon-
strates the variability in time from orphan drug designa-
tion to approval for the various technology platforms
and conditions.
Figure 1 Number of orphan drug designations (open bars) and FDA approvals (full bars) for compounds intended to treat lysosomal storage
diseases by year.
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1) Prevalence of disease
The proportions of drugs receiving FDA approval and
orphan drug designations were higher in rare diseases
than in very rare diseases: of the 14 FDA approved
drugs, 12 were for more frequent lysosomal storage dis-
eases (prevalence ≥ 5/1,000,000) and only two were for
less frequent conditions (prevalence < 5/1,000,000; p =
0.00742) (Table 2). Likewise, orphan drug designations
were granted for 45 drugs developed to treat lysosomal
storage disorders with a prevalence of ≥ 5/1,000,000,
whereas only 25 drugs for less frequent diseases with a
prevalence of < 5/1,000,000 received orphan drug desig-
nations, and in 17 very rare diseases, there was no drug
in development at all (p < 0.0001).
2) Neurological vs somatic endpoints and biomarkers
Neurological endpoints were statistically significant fac-
tors for successful drug development and orphan drug
designations (Table 2). Of the approved 14 compounds,
no clinical development program had a primary neuro-
logical endpoint. Most, i.e. 51/70 (72.9%), orphan drug
designations were sought for diseases that would, by na-
ture of the disease, not require a neurological endpoint
in clinical studies. In contrast, most conditions without
an orphan drug designation, i.e. 15/17 (88.2%), would re-
quire a clinical trial with a neurological endpoint. Three
successful orphan drug programs were based on bio-
markers, i.e. in Gaucher disease, Fabry disease, and cysti-
nosis (Table 1). The time to FDA approval for these threeconditions tended to be shorter than for conditions with
clinical endpoints, although the difference was not statisti-
cally different.
3) Regulatory precedent
Regulatory precedent, i.e. a drug approval in the same or a
clinically very similar disease (e.g. the MPS group), was a
statistically significant factor for orphan drug designation
in lysosomal storage diseases (Table 2). Most orphan drug
designations, i.e. 39/70 (55.7%) had a regulatory precedent
whereas, accordingly, there was no regulatory precedent
for the majority of lysosomal storage diseases without or-
phan drug status, i.e. 16/17 (94.1%, p = 0.00022).
4) Technology platforms
Approved therapies were enzyme replacement therapies
(N = 10), small molecules (N = 3), and substrate reduc-
tion therapies (N = 1) as shown in Table 1. The most fre-
quent orphan drug designations were enzymes of
various sources and modified enzymes (N = 40), gene
therapies (N = 9), small molecules (N = 6), substrate re-
duction therapies (N = 6), chaperones (N = 6), stem cell
therapy (N = 1), and others (N = 2) as shown in Figure 4.
Discussion
In the last three decades from 1983 until 2013, fourteen
drugs for seven lysosomal storage disorders received FDA
approval.
There were four factors that played a key role in suc-
cessful orphan drug development or orphan drug designa-
tions: 1) prevalence of disease 2) endpoints 3) regulatory
Table 1 FDA approved compounds for lysosomal storage disorders, endpoints and design of clinical trials
Disease Compound Therapeutic class Endpoints in pivotal studies Primary
neurological
endpoints
Biomarker
endpoints
Regulatory
precedent
Pivotal trial design Ref.
MPS I Laronidase Enzyme Forced vital capacity (% of predicted),
6 min walk distance
No No No RCT, 26 weeks, N = 45, mean age
15.5 years (range 6 – 43 years)
[24]
MPS II Idursulfase Enzyme Forced vital capacity (% of predicted),
6 min walk distance
No No Yes RCT, 53 weeks, N = 96, mean age
14.2 years (range 5–31 years)
[25]
MPS VI Galsulfase Enzyme 12 min walk distance, 3 min stair
climb test (stairs/min)
No No Yes RCT, 24 weeks, N = 39,
(age range 5–29 years)
[26]
Gaucher disease
type I
Alglucerase Enzyme Liver and spleen volume change,
Hematologic deficiencies, improved
mineralization of bone, cachexia and wasting
No Yes No OLT, 36 – 52 weeks, N = 13, mean
age 20.3 years (range 7–42 years)
[27]
Gaucher disease Imiglucerase Enzyme Anemia and thrombocytopenia, liver and
spleen volume change, decreased cachexia
No Yes Yes RCT, 26 weeks, N = 30, mean age
32.7 years (range 12 – 69 years)
[28]
Gaucher disease Taliglucerase alfa Enzyme Hemoglobin concentration, platelet count,
liver and spleen volume change
No Yes Yes RCT, 36 weeks, N = 32, mean age
36.2 years (range 19 – 74 years)
[29]
Gaucher disease Velaglucerase alfa Enzyme Hemoglobin concentration, platelet count,
liver and spleen volume change
No Yes Yes RCT, N = 25, 52 weeks, median
age 25 years, (range 4–62 years)
[30]
Gaucher disease Miglustat Substrate reduction Liver and spleen volume change,
hemoglobin concentration, platelet count
No Yes Yes OLT, 52 weeks, N = 28, mean age
44 years (range 22–69 years)
[31]
Fabry disease Agalsidase beta Enzyme Reduction of GL-3 inclusions in capillary
endothelium of kidney, heart and skin
No Yes No RCT, 20 weeks, N = 58, mean age
30.2 years (range 16–61 years)
[32]
Pompe disease Alglucosidase alfa Enzyme (bioreactor
size: 160 L)
Number of patients who died or needed
invasive ventilator support
No No No OLT, 52–106 weeks, N = 18, age
range 1 month to 3.5 years
[33]
Pompe disease Alglucosidase alfa Enzyme (bioreactor
size: 4000 L)
Forced vital capacity (% of predicted),
6 min walking distance
No No No RCT, 78 weeks, N = 90, mean age
44.4 years (range 10–70 years)
[34]
Cystinosis Cysteamine bitartrate IR Small molecule Serum creatinine, calculated creatinine
clearance, growth (height)
No Yes No OLT, N = 94, mean age 3.8 years [35]
Cystinosis Cysteamine ophtalmic solution Small molecule Corneal Cystine Crystal Score No Yes No OLT, N = 283 (three studies) [36]
Cystinosis Cysteamine bitartrate DR Small molecule White blood cell cystine No Yes Yes RCT, N = 43, mean age 12
years (range 6 – 26 years)
[37]
RCT – randomized controlled trial, OLT – open label trial, IR – immediate release, DR – delayed-release, GL-3 – globotriaosylceramide.
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Figure 2 Time to approval of compounds intended to treat lysosomal storage diseases by A) technology platform and B) disease. Lines indicate means.
Mechler et al. Orphanet Journal of Rare Diseases  (2015) 10:46 Page 5 of 9precedent, and 4) technology platform. These data demon-
strate that the efforts in drug development were directed
towards more common diseases. Primarily neurological
diseases were neglected, and clinical trials utilized either
somatic or biomarker endpoints. Clinical studies were
mainly small clinical trials. Enzyme replacement therapy
was the most successful technology in the last three de-
cades followed by small molecules and substrate reduction.
One may think that the successful development of a
therapy would stop further activities in the area. The
contrary seems to be the case: innovation seeds innova-
tions and success leads to more development pressure.
Once a drug is approved, further orphan drug designa-
tions follow on as illustrated in Figure 2B. Enzyme re-
placement therapy for non-neurological Gaucher disease
was the condition that seeded and orthodromically
drove innovation. In addition to being the first, Gaucher
disease also has the most approved therapies and most
orphan drug designations. This may not be a coinci-
dence, because Gaucher disease is a more frequent con-
dition and the FDA approval was based on biomarkersas well as visceral endpoints which show timely and sub-
stantial treatment effects. Biomarker based programs,
such as Gaucher disease and cystinosis tended to have
shorter timelines from orphan drug designation to FDA
approval.
Neurological endpoints appear to be problematic. Often,
the natural history of the neurological disease is ill defined,
validated quantitative endpoints across languages are not
available or the treatment does not address the neuro-
logical manifestation of the disease as exemplified by two
studies of enzyme replacement therapy and substrate re-
duction therapy in neuronopathic Gaucher disease [9,10].
The fact that neurological diseases received less attention
is obviously not intentional. It is due to the types of drugs
in development, and in particular, their mechanisms of ac-
tion, and their ability to target sites of pathology across
the blood brain barrier.
Regulatory precedent, i.e. the approval of a compound
in the same disease or similar disease group, sets the
pathway for successful downstream drug development
in the same or a very similar condition. In the case of
Figure 3 Year of orphan drug designation for compounds intended to treat lysosomal storage diseases. A) by technology platform. B) by disease.
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als shared almost identical endpoints across programs,
which may have facilitated the design of pivotal studies
as the true validation of clinical endpoints in single rare
diseases is complicated by the small size of available
study populations and the slowly progressive nature of
most diseases [11-13]. Likewise, the dialogue with the
FDA becomes easier once the agency has become famil-
iar with similar questions from a previous, successful
drug development program. Interestingly, although ap-
provals were focused on endpoints documenting the
initial therapeutic response, the trials which have led to
regulatory approval have not addressed the lifetime re-
quirement for treatment and maintenance regimen.Most approved and designated orphan drugs were en-
zymes. Substituted enzymes tend to work well on som-
atic endpoints and biomarkers as demonstrated in the
successful clinical development programs outlined in
Table 1, but the effect of enzyme replacement therapy is
mainly compromised by late initiation of treatment, im-
mune reactions against the therapeutic protein as well
as incomplete accessibility of certain tissues by the pro-
tein such as skeletal muscle, bone, and especially brain
[14-17]. Dose and frequency of enzyme administration
are further important questions [18]. These shortcom-
ings will direct future research.
Other successful approvals were small molecules and
substrate reduction. If a lysosomal storage disease is of
Figure 4 Orphan drug designations for compounds intended to
treat lysosomal storage disorders by technology platforms and
diseases. N indicates number of orphan drug designations granted.
Bold indicates orphan drug designation across two or more
technology platforms. “A” indicates disease with one or more FDA
approved therapies in the particular technology platform.
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data would suggest low development pressure and low
probability of success. This is illustrated by programs such
as Niemann-Pick disease type C and Batten disease pro-
grams which neither led to the detection of strong thera-
peutic effects size or to FDA approval [19,20].
What must be done to address unmet needs for ultra-
rare and neuronopathic lysosmal storage disorders? Vari-
ous traditional and innovative technology platforms are
being tested in human. As such, clinicaltrials.gov cur-
rently lists more than 70 open interventional clinical tri-
als for lysosomal storage disorders studying enzymes,
modified enzymes, substrate reduction, intrathecal drug
delivery, chaperone therapy, hematopoetic stem cell
transplantation, small molecules and gene therapy [21].
The results of this work will provide further insight intoTable 2 Statistical analysis of clinical, regulatory, and
epidemiological factors associated with a) FDA approval
for compounds intended to treat lysosomal storage
disorders and b) orphan drug designation
a)
Characteristic FDA approval
(N = 14)
No FDA
approval
(N = 73)
P-value*
Neurological endpoint 0 (0%) 34 (46.6%) 0.00059
No neurological endpoint 14 (100%) 39 (53.4%)
Regulatory precedent 9 (64.3%) 31 (42.5%) 0.15411
No regulatory precedent 5 (35.7%) 42 (57.5%)
Prevalence < 5/1,000,000 2 (14.3%) 40 (54.8%) 0.00742
Prevalence≥ 5/1,000,000 12 (85.7%) 33 (45.2%)
Orphan status designation 14 (100%) 56 (76.7%) 0.06229
No orphan status
designation
0 (0%) 17 (23.3%)
b)
Characteristic Orphan status
(N = 70)
No orphan
status (N = 17)
P-value*
Neurological endpoint 19 (27.1%) 15 (88.2%) < 0.0001
No neurological endpoint 51 (72.9%) 2 (11.8%)
Regulatory precedent 39 (55.7%) 1 (5.9%) 0.00022
No regulatory precedent 31 (44.3%) 16 (94.1%)
Prevalence < 5/1,000,000 25 (35.7%) 17 (100%) < 0.0001
Prevalence≥ 5/1,000,000 45 (64.3%) 0 (0%)
*P-values are from Fisher’s Exact Test.
Mechler et al. Orphanet Journal of Rare Diseases  (2015) 10:46 Page 8 of 9the ability to cure CNS diseases. Drug development in
neuronopathic lysosomal storage disorders may be facili-
tated through the availability of better instruments
assessing neurological and behavioral functions in a
standardized way as proposed in the NIH toolbox [22].
Quantitative natural history studies are indispensable for
a better understanding of the disease, design of clinical
trials and the assessment of potential treatment effects.
Biomarker development and better access to biomarker-
based approvals as in Gaucher disease and cystinosis
may be other points of consideration [23]. All the 14
FDA-approved compounds were developed by eight
mainly small, specialized biopharmaceutical companies
which have, in general, experienced sustainable eco-
nomic growth over time.
Limitations of this analysis
First, the designation of a compound as an orphan drug
was considered a surrogate for the intent to develop a
drug for a disease. Due to patent considerations, not all
manufacturers may seek orphan drug designation by the
FDA and information may therefore not be transparent.
Second, time to approval may not reflect true develop-
ment process because the time of orphan designation
may be arbitrary in the drug development process.
Third, the European Medicine Agency data were not for-
mally analyzed, mainly because orphan legislation was in-
troduced much later (2000) and the database is therefore
less comprehensive. As drug development for orphan con-
ditions is a global effort, and as the EMA orphan drug
designations show similar trends (data not shown) the for-
mal analysis of the FDA data and their impact for patients
around the world are considered generalizable.
Conclusions
Since the introduction of the US orphan drug act in
1983 until 2013, 14 orphan drugs, mostly enzyme re-
placement therapies, were developed for lysosomal stor-
age disorders. Drug development was driven by more
frequent conditions and diseases with somatic or bio-
marker endpoints sharing a similar pathway to registra-
tion. Successful development seeded further innovation.
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